|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2000; 36:751-757 © 2000 by the American College of Cardiology Foundation |
* Institute of Medical Biology and Human Genetics, University of Innsbruck, Innsbruck, Austria
Innsbruck University Hospital, Department of Cardiology, Innsbruck, Austria
Department of Clinical Biochemistry, Christian Medical College and Hospital, Vellore, India
Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Universität Münster, Münster, Germany
Manuscript received December 23, 1999; revised manuscript received March 1, 2000, accepted April 13, 2000.
Reprint requests and correspondence: Dr. Florian Kronenberg, Institute of Medical Biology and Human Genetics, University of Innsbruck, Schöpfstrasse 41, A-6020 Innsbruck, Austria
Florian.Kronenberg{at}uibk.ac.at
OBJECTIVES
The objective of this study was to evaluate the relation between apolipoprotein A-IV (apoA-IV) plasma concentrations and coronary artery disease (CAD).
BACKGROUND
Experimental in vitro and in vivo studies favor apoA-IV to be protective against the development of atherosclerosis. Mice that overexpress either human or mouse apoA-IV demonstrated a significant reduction of aortic atherosclerotic lesions compared with control mice. Data on apoA-IV plasma concentrations and CAD in humans are lacking.
METHODS
We determined in two independent case-control studies of a Caucasian and an Asian Indian population whether apoA-IV plasma concentrations are related to the presence of angiographically assessed CAD.
RESULTS
Plasma apoA-IV levels were significantly lower in 114 male Caucasian subjects with angiographically defined CAD when compared with 114 age-adjusted male controls (10.2 ± 3.8 mg/dL vs. 15.1 ± 4.0 mg/dL, p < 0.001). Logistic regression analysis indicated that the association between apoA-IV levels and CAD was independent of the high-density lipoprotein cholesterol and triglyceride concentrations. The inverse relationship between plasma levels of apoA-IV and the presence of CAD was confirmed in an independent sample of 68 male Asian Indians with angiographically documented CAD and 68 age-matched controls.
CONCLUSIONS
The results of this cross-sectional study demonstrate for the first time an association between low apoA-IV concentrations and CAD in humans and suggest that apoA-IV may play an antiatherogenic role in humans.
| ||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  M. R. Tubb, R. A. G. D. Silva, K. J. Pearson, P. Tso, M. Liu, and W. S. Davidson Modulation of Apolipoprotein A-IV Lipid Binding by an Interaction between the N and C Termini J. Biol. Chem., September 28, 2007; 282(39): 28385 - 28394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Archer, D. Sauvaget, V. Chauffeton, P.-E. Bouchet, J. Chambaz, M. Pincon-Raymond, P. Cardot, A. Ribeiro, and M. Lacasa Intestinal Apolipoprotein A-IV Gene Transcription Is Controlled by Two Hormone-Responsive Elements: A Role for Hepatic Nuclear Factor-4 Isoforms Mol. Endocrinol., September 1, 2005; 19(9): 2320 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-m. R. Wong, J. W. Stephens, J. Acharya, S. J. Hurel, S. E. Humphries, and P. J. Talmud The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease J. Lipid Res., August 1, 2004; 45(8): 1565 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liang, X.-C. Jiang, R. Liu, G. Liang, T. P. Beyer, H. Gao, T. P. Ryan, S. Dan Li, P. I. Eacho, and G. Cao Liver X Receptors (LXRs) Regulate Apolipoprotein AIV-Implications of the Antiatherosclerotic Effect of LXR Agonists Mol. Endocrinol., August 1, 2004; 18(8): 2000 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rafat, A. M. Sattler, R. Hackler, M. Soufi, A. Steinmetz, B. Maisch, and J. R. Schaefer Apolipoprotein A-IV in the Fed and Fasting States Clin. Chem., July 1, 2004; 50(7): 1270 - 1271. [Full Text] [PDF]
|
|
|
|
|
|
B. Ezeh, M. Haiman, H. F. Alber, B. Kunz, B. Paulweber, A. Lingenhel, H.-G. Kraft, F. Weidinger, O. Pachinger, H. Dieplinger, et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls J. Lipid Res., August 1, 2003; 44(8): 1523 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Aouizerat, M. Kulkarni, D. Heilbron, D. Drown, S. Raskin, C. R. Pullinger, M. J. Malloy, and J. P. Kane Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids J. Lipid Res., June 1, 2003; 44(6): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kratz, U. Wahrburg, A. von Eckardstein, B. Ezeh, G. Assmann, and F. Kronenberg Dietary Mono- and Polyunsaturated Fatty Acids Similarly Increase Plasma Apolipoprotein A-IV Concentrations in Healthy Men and Women J. Nutr., June 1, 2003; 133(6): 1821 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-m. R. Wong, E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels Circ. Res., May 16, 2003; 92(9): 969 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kronenberg, E. Kuen, E. Ritz, P. Konig, G. Kraatz, K. Lhotta, J. F. E. Mann, G. A. Muller, U. Neyer, W. Riegel, et al. Apolipoprotein A-IV Serum Concentrations Are Elevated in Patients with Mild and Moderate Renal Failure J. Am. Soc. Nephrol., February 1, 2002; 13(2): 461 - 469. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
